Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 3,529–3,536 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Regeneron Pharmaceuticals Inc. Neoadjuvant Cemiplimab Stage II to IV Cutaneous Squamous Cell Carcinoma (CSCC) Phase 2 Ongoing Intravenous Oncology
Regeneron Pharmaceuticals Inc. Libtayo (cemiplimab) Stage II to IV resectable cutaneous squamous cell carcinoma (CSCC) Phase 2 Ongoing Intravenous Oncology
Regeneron Pharmaceuticals Inc. REGN5381 Hearth failure Phase 2 Enrollment Initiation Intravenous Cardiology
Regeneron Pharmaceuticals Inc. Ateganosine (THIO-101) Non-small cell lung cancer (NSCLC) Phase 2 Data Released Oral Oncology
Regeneron Pharmaceuticals Inc. Vidutolimod and Libtayo (cemiplimab) Cutaneous Squamous Cell Carcinoma (CSCC) Phase 2 Ongoing Intratumoral and intravenous Oncology
Regeneron Pharmaceuticals Inc. Vidutolimod (CMP-001) and KEYTRUDA (pembrolizumab) Head and neck squamous cell carcinoma (HNSCC) Phase 2 Ongoing Vidutolimod intratumoral KEYTRUDA intravenous Oncology
Regeneron Pharmaceuticals Inc. Vidutolimod (CMP-001) and OPDIVO (nivolumab) Melanoma Phase 2 Ongoing Intratumoral and intravenous Oncology
Regeneron Pharmaceuticals Inc. Vidutolimod (CMP-001) and KEYTRUDA (pembrolizumab) Melanoma Phase 2 Ongoing Vidutolimod intratumoral KEYTRUDA intravenous Oncology